Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artios Pharma Limited

https://www.artiospharma.com/

Latest From Artios Pharma Limited

Rock-Bottom Interest Rates Have 'Turbo Charged Growth In Frontier Sectors'

A report from Silicon Valley Bank breaking down 2021 investment trends reveals half-year figures already close to matching those for the whole of 2020 – itself a record-breaking year. In Vivo spoke with SVB’s EMEA head of life sciences and health care for a deeper dive into underlying causes.

Deals Digital Health

Finance Watch: A Summer Slowdown? Not For Venture Capital Mega-Rounds

Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.

Financing Innovation

Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals

Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.

Financing Innovation

Novartis Broadens VISION On Radioligands

Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge. 

ASCO Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register